Continuous renal replacement therapy (CRRT / haemofiltration)
CRRT · Critical Care / ICU
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Continuous veno-venous haemofiltration (convection ± dialysis = CVVHDF) via a double-lumen catheter: gentle continuous fluid and solute control suited to unstable ICU patients — the standard ICU modality (intermittent HD suits stable patients; PD is largely superseded in adult ICU).
Red flags
- Do NOT delay CRRT for a dialysable life-threat while “optimising”
- Citrate toxicity: rising total:ionised calcium ratio, worsening acidosis
Management
- Urgent indications: refractory hyperkalaemia >6.5, refractory acidosis, diuretic-resistant fluid overload, uraemic complications (pericarditis/encephalopathy), selected toxins (SLED/HD for lithium, toxic alcohols)
- Prescribe effluent dose 20–25 mL/kg/h (higher doses show no benefit — RENAL/ATN trials); pre/post-dilution per circuit
- Anticoagulation: regional citrate (first-line where available — watch ionised calcium and citrate accumulation) or heparin; none if coagulopathic
- Vascular access: right IJ preferred; avoid subclavian (stenosis)
- Watch: hypotension on connection, hypophosphataemia/hypokalaemia with prolonged therapy, drug dose adjustments, circuit clotting
Exam pearls
- 2020s update: accelerated (pre-emptive) initiation shows no benefit over watchful waiting with clear triggers (STARRT-AKI 2020)
Continuous, gentle, titratable — the unstable kidney’s best friend; dose ~25 mL/kg/h and protect the circuit.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.